Insider Selling: Progyny (NASDAQ:PGNY) CFO Sells 8,275 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 8,275 shares of Progyny stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $25.50, for a total transaction of $211,012.50. Following the completion of the transaction, the chief financial officer owned 79,063 shares in the company, valued at approximately $2,016,106.50. The trade was a 9.47% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Performance

NASDAQ:PGNY traded down $0.95 during trading hours on Thursday, reaching $24.69. The company’s stock had a trading volume of 1,424,301 shares, compared to its average volume of 1,560,195. The firm has a market capitalization of $1.93 billion, a price-to-earnings ratio of 32.06, a PEG ratio of 1.31 and a beta of 0.91. The firm has a 50-day simple moving average of $18.78 and a 200-day simple moving average of $21.97. Progyny, Inc. has a 1 year low of $16.10 and a 1 year high of $28.75.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, May 7th. The company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. The company had revenue of $328.50 million for the quarter, compared to analysts’ expectations of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm’s revenue was down 26.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities analysts anticipate that Progyny, Inc. will post 1.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on PGNY shares. Weiss Ratings reiterated a “hold (c)” rating on shares of Progyny in a research report on Friday, March 27th. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. KeyCorp decreased their target price on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, March 2nd. JPMorgan Chase & Co. set a $35.00 target price on shares of Progyny in a research report on Wednesday, January 21st. Finally, Citigroup restated an “outperform” rating on shares of Progyny in a research report on Monday, May 11th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $29.55.

Hedge Funds Weigh In On Progyny

Hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd purchased a new position in shares of Progyny in the fourth quarter valued at about $25,000. Federated Hermes Inc. increased its position in shares of Progyny by 147.3% in the third quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock valued at $30,000 after acquiring an additional 819 shares during the period. Hantz Financial Services Inc. increased its position in shares of Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock valued at $43,000 after acquiring an additional 742 shares during the period. Covestor Ltd boosted its stake in shares of Progyny by 164.9% during the 3rd quarter. Covestor Ltd now owns 2,609 shares of the company’s stock valued at $56,000 after purchasing an additional 1,624 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in shares of Progyny during the 2nd quarter valued at about $77,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.